SMN1 and proximal spinal muscular atrophy: Genetic therapies based on ASOs and AAV-gene delivery have been demonstrated to be successful in patients with spinal muscular atrophy (SMA), the disease caused by the mutation of the survival motor neuron 1 (SMN1) gene.